1
LAYTON MARK E: Imidazopyridin-2-one derivatives. MERCK SHARP & DOHME, March 24, 2011: WO/2011/034741 (14 worldwide citation)

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...


2
Zoller Gerhard, Petry Stefan, Follmann Markus, Müller Günter, Tennagels Norbert: Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase. Sanofi Aventis, Zoller Gerhard, Petry Stefan, Follmann Markus, Müller Günter, Tennagels Norbert, October 4, 2007: WO/2007/110215 (14 worldwide citation)

The present invention relates to imidazopyridin-2-one derivatives of the formula (I) with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments. The compounds are inhibitors of endothelial lipase.


3
Gerhard Zoller, Stefan Petry, Markus Follmann, Gunter Muller, Norbert Tennagels: Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases. Sanofi Aventis, Scully Scott Murphy & Presser P C, March 1, 2011: US07897616 (3 worldwide citation)

The present invention relates to imidazopyridin-2-one derivatives of the formula I with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments.


4
OHTSUKA MASAMI, HAGINOYA NORIYASU, ICHIKAWA MASANORI, MATSUNAGA HIRONORI, SAITO HIRONAO, SHIBATA YOSHIHIRO, TSUNEMI TOMOYUKI: DERIVE DIMIDAZOPYRIDIN-2-ONE, IMIDAZOPYRIDIN-2-ONE DERIVATIVES. DAIICHI SANKYO COMPANY, DAIICHI SANKYO COMPANY, MARKS & CLERK, October 1, 2013: CA2732950 (2 worldwide citation)

There is provided a compound represented by the following formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof. [In the formula (I), A is a 8- to 10-membered partially saturated or aromatic fused bicyclic nitrogen-containing heterocyclic group having 1 to 3 nitr ...


5
FIJI Hannah D, KELLY Michael J III, KERN Jeffrey C, LAYTON Mark E, PERO Joseph E, REIF Alexander J, ROSSI Michael A: DÉRIVÉS DIMIDAZOPYRIDIN-2-ONE, IMIDAZOPYRIDIN-2-ONE DERIVATIVES. MERCK SHARP & DOHME, FIJI Hannah D, KELLY Michael J III, KERN Jeffrey C, LAYTON Mark E, PERO Joseph E, REIF Alexander J, ROSSI Michael A, December 20, 2012: WO/2012/174199 (1 worldwide citation)

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...


6

7
Hannah D Fiji, Michael J Kelly III, Jeffrey C Kern, Mark E Layton, Joseph E Pero, Alexander J Reif, Michael A Rossi: Imidazopyridin-2-one derivatives. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, April 19, 2016: US09315518

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...


8

9
Zoller Gerhard, Petry Stefan, Follmann Markus, Mueller Guenter, Tennagels Norbert: Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase. Sanofi Aventis, December 17, 2008: EP2001878-A1

Die vorliegende Erfindung betrifft Imidazopyridin-2-on-derivate der allgemeinen Formel I mit den in der Beschreibung angegebenen Bedeutungen, deren pharmazeutisch anwendbare Salze und deren Verwendung als Arzneistoffe. $F1


10
Gerhard Zoller, Stefan Petry, Markus Follmann, Gunter Muller, Norbert Tennagels: Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases. Sanofi Aventis, Andrea Q Ryan, Sanofi Aventis Us, March 19, 2009: US20090076068-A1

The present invention relates to imidazopyridin-2-one derivatives of the formula I with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments.



Click the thumbnails below to visualize the patent trend.